- Home
- Publications
- Publication Search
- Publication Details
Title
Novel targeted agents for the treatment of advanced breast cancer
Authors
Keywords
-
Journal
Future Medicinal Chemistry
Volume 4, Issue 7, Pages 893-914
Publisher
Future Science, LTD
Online
2012-05-10
DOI
10.4155/fmc.12.45
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Randomized, double-blind, placebo-controlled, phase III study of bevacizumab with docetaxel or docetaxel with placebo as first-line therapy for patients with locally recurrent or metastatic breast cancer (mBC): AVADO.
- (2017) D. Miles et al. JOURNAL OF CLINICAL ONCOLOGY
- A phase I study of trastuzumab-DM1 (T-DM1), a first-in-class HER2 antibody-drug conjugate (ADC), in patients (pts) with advanced HER2+ breast cancer (BC)
- (2017) M. Beeram et al. JOURNAL OF CLINICAL ONCOLOGY
- TBCRC 006: A multicenter phase II study of neoadjuvant lapatinib and trastuzumab in patients with HER2-overexpressing breast cancer.
- (2017) J. C. N. Chang et al. JOURNAL OF CLINICAL ONCOLOGY
- Fibroblast Growth Factors in Development and Cancer: Insights from the Mammary and Prostate Glands
- (2012) Kathryn Schwertfeger CURRENT DRUG TARGETS
- First-Line Treatment of Advanced Breast Cancer With Sunitinib in Combination With Docetaxel Versus Docetaxel Alone: Results of a Prospective, Randomized Phase III Study
- (2012) Jonas Bergh et al. JOURNAL OF CLINICAL ONCOLOGY
- Trastuzumab-Induced Cardiotoxicity: Heart Failure at the Crossroads
- (2012) Partho P. Sengupta et al. MAYO CLINIC PROCEEDINGS
- Bevacizumab Added to Neoadjuvant Chemotherapy for Breast Cancer
- (2012) Harry D. Bear et al. NEW ENGLAND JOURNAL OF MEDICINE
- Neoadjuvant Chemotherapy and Bevacizumab for HER2-Negative Breast Cancer
- (2012) Gunter von Minckwitz et al. NEW ENGLAND JOURNAL OF MEDICINE
- Phase II study of single-agent bosutinib, a Src/Abl tyrosine kinase inhibitor, in patients with locally advanced or metastatic breast cancer pretreated with chemotherapy
- (2011) M. Campone et al. ANNALS OF ONCOLOGY
- A phase II study of the histone deacetylase inhibitor vorinostat combined with tamoxifen for the treatment of patients with hormone therapy-resistant breast cancer
- (2011) P N Munster et al. BRITISH JOURNAL OF CANCER
- Trastuzumab Emtansine (T-DM1): A Novel Agent for Targeting HER2+ Breast Cancer
- (2011) Howard A. Burris et al. Clinical Breast Cancer
- Iniparib Nonselectively Modifies Cysteine-Containing Proteins in Tumor Cells and Is Not a Bona Fide PARP Inhibitor
- (2011) X. Liu et al. CLINICAL CANCER RESEARCH
- HSP90 Inhibition Is Effective in Breast Cancer: A Phase II Trial of Tanespimycin (17-AAG) Plus Trastuzumab in Patients with HER2-Positive Metastatic Breast Cancer Progressing on Trastuzumab
- (2011) S. Modi et al. CLINICAL CANCER RESEARCH
- Adenoid Cystic Carcinoma, Low-Differentiation Carcinoma, Squamous Cell Carcinoma: A Rare Evolution of a Tracheal Malignancy Within 27 Years
- (2011) Xiaoying Wang et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase I/II Study of Trastuzumab in Combination With Everolimus (RAD001) in Patients With HER2-Overexpressing Metastatic Breast Cancer Who Progressed on Trastuzumab-Based Therapy
- (2011) Phuong K. Morrow et al. JOURNAL OF CLINICAL ONCOLOGY
- Randomized, Placebo-Controlled, Double-Blind, Phase II Study of Axitinib Plus Docetaxel Versus Docetaxel Plus Placebo in Patients With Metastatic Breast Cancer
- (2011) Hope S. Rugo et al. JOURNAL OF CLINICAL ONCOLOGY
- Unmeasured Costs of a Child's Death: Perceived Financial Burden, Work Disruptions, and Economic Coping Strategies Used by American and Australian Families Who Lost Children to Cancer
- (2011) Veronica Dussel et al. JOURNAL OF CLINICAL ONCOLOGY
- RIBBON-1: Randomized, Double-Blind, Placebo-Controlled, Phase III Trial of Chemotherapy With or Without Bevacizumab for First-Line Treatment of Human Epidermal Growth Factor Receptor 2–Negative, Locally Recurrent or Metastatic Breast Cancer
- (2011) Nicholas J. Robert et al. JOURNAL OF CLINICAL ONCOLOGY
- Motesanib, or open-label bevacizumab, in combination with paclitaxel, as first-line treatment for HER2-negative locally recurrent or metastatic breast cancer: a phase 2, randomised, double-blind, placebo-controlled study
- (2011) Miguel Martin et al. LANCET ONCOLOGY
- Combating trastuzumab resistance by targeting SRC, a common node downstream of multiple resistance pathways
- (2011) Siyuan Zhang et al. NATURE MEDICINE
- Iniparib plus Chemotherapy in Metastatic Triple-Negative Breast Cancer
- (2011) Joyce O'Shaughnessy et al. NEW ENGLAND JOURNAL OF MEDICINE
- Everolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast Cancer
- (2011) José Baselga et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer
- (2011) José Baselga et al. NEW ENGLAND JOURNAL OF MEDICINE
- Bevacizumab Treatment for Advanced Breast Cancer
- (2011) R. H. Alvarez et al. ONCOLOGIST
- Targeting the Phosphatidylinositol 3-Kinase Signaling Pathway in Breast Cancer
- (2011) L. F. Hernandez-Aya et al. ONCOLOGIST
- Phase III Multicenter Clinical Trial of the Sialyl-TN (STn)-Keyhole Limpet Hemocyanin (KLH) Vaccine for Metastatic Breast Cancer
- (2011) D. Miles et al. ONCOLOGIST
- A review of PARP inhibitors: from bench to bedside
- (2010) C. Underhill et al. ANNALS OF ONCOLOGY
- The Anti-Tumor Effect of Motesanib in Pre-Clinical Models of Human Basal-Like Breast Cancer.
- (2010) J. Price et al. CANCER RESEARCH
- Final Results of a Randomized Phase II Study Demonstrating Efficacy and Safety of BSI-201, a Poly (ADP-Ribose) Polymerase (PARP) Inhibitor, in Combination with Gemcitabine/Carboplatin (G/C) in Metastatic Triple Negative Breast Cancer (TNBC).:
- (2010) J. O'Shaughnessy et al. CANCER RESEARCH
- Biological Evidence for Dual Antiangiogenic-Antiaromatase Activity of the VEGFR Inhibitor PTK787/ZK222584 In vivo
- (2010) S. Banerjee et al. CLINICAL CANCER RESEARCH
- Vandetanib with docetaxel as second-line treatment for advanced breast cancer: a double-blind, placebo-controlled, randomized Phase II study
- (2010) Katalin Boér et al. INVESTIGATIONAL NEW DRUGS
- Phase I Study of Everolimus Plus Weekly Paclitaxel and Trastuzumab in Patients With Metastatic Breast Cancer Pretreated With Trastuzumab
- (2010) Fabrice Andre et al. JOURNAL OF CLINICAL ONCOLOGY
- Neratinib, an Irreversible ErbB Receptor Tyrosine Kinase Inhibitor, in Patients With Advanced ErbB2-Positive Breast Cancer
- (2010) Harold J. Burstein et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II Trial of Pertuzumab and Trastuzumab in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer That Progressed During Prior Trastuzumab Therapy
- (2010) José Baselga et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase III Randomized Study Comparing Docetaxel Plus Trastuzumab With Vinorelbine Plus Trastuzumab As First-Line Therapy of Metastatic or Locally Advanced Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: The HERNATA Study
- (2010) Michael Andersson et al. JOURNAL OF CLINICAL ONCOLOGY
- A Phase II Study of Pazopanib in Patients with Recurrent or Metastatic Invasive Breast Carcinoma: A Trial of the Princess Margaret Hospital Phase II Consortium
- (2010) S. K. Taylor et al. ONCOLOGIST
- Amplification of fibroblast growth factor receptor-1 in breast cancer and the effects of brivanib alaninate
- (2009) Christine Y. Shiang et al. BREAST CANCER RESEARCH AND TREATMENT
- A randomized, phase II, dose-finding study of the pan-ErbB receptor tyrosine-kinase inhibitor CI-1033 in patients with pretreated metastatic breast cancer
- (2009) Olivier Rixe et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Multicenter Phase II Study of Lapatinib in Patients with Brain Metastases from HER2-Positive Breast Cancer
- (2009) N. U. Lin et al. CLINICAL CANCER RESEARCH
- Histone Deacetylase Inhibitors in Cancer Therapy
- (2009) Andrew A. Lane et al. JOURNAL OF CLINICAL ONCOLOGY
- Concurrent Trastuzumab and HER2/neu-Specific Vaccination in Patients With Metastatic Breast Cancer
- (2009) Mary L. Disis et al. JOURNAL OF CLINICAL ONCOLOGY
- Lapatinib Combined With Letrozole Versus Letrozole and Placebo As First-Line Therapy for Postmenopausal Hormone Receptor–Positive Metastatic Breast Cancer
- (2009) Stephen Johnston et al. JOURNAL OF CLINICAL ONCOLOGY
- Trastuzumab Plus Anastrozole Versus Anastrozole Alone for the Treatment of Postmenopausal Women With Human Epidermal Growth Factor Receptor 2–Positive, Hormone Receptor–Positive Metastatic Breast Cancer: Results From the Randomized Phase III TAnDEM Study
- (2009) Bella Kaufman et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II Randomized Study of Neoadjuvant Everolimus Plus Letrozole Compared With Placebo Plus Letrozole in Patients With Estrogen Receptor–Positive Breast Cancer
- (2009) José Baselga et al. JOURNAL OF CLINICAL ONCOLOGY
- Trastuzumab Beyond Progression in Human Epidermal Growth Factor Receptor 2–Positive Advanced Breast Cancer: A German Breast Group 26/Breast International Group 03-05 Study
- (2009) Gunter von Minckwitz et al. JOURNAL OF CLINICAL ONCOLOGY
- The HER-2 Receptor and Breast Cancer: Ten Years of Targeted Anti-HER-2 Therapy and Personalized Medicine
- (2009) J. S. Ross et al. ONCOLOGIST
- Specific apoptosis induction by the dual PI3K/mTor inhibitor NVP-BEZ235 in HER2 amplified and PIK3CA mutant breast cancer cells
- (2009) Saskia M. Brachmann et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- HER2-targeted therapy in breast cancer. Monoclonal antibodies and tyrosine kinase inhibitors
- (2008) Dorte Lisbet Nielsen et al. CANCER TREATMENT REVIEWS
- A Phase II Trial of Erlotinib in Combination with Bevacizumab in Patients with Metastatic Breast Cancer
- (2008) M. N. Dickler et al. CLINICAL CANCER RESEARCH
- Results of the First Phase I Clinical Trial of the Novel Ii-Key Hybrid Preventive HER-2/neuPeptide (AE37) Vaccine
- (2008) Jarrod P. Holmes et al. JOURNAL OF CLINICAL ONCOLOGY
- Recurrent Priapism Related to Oxaliplatin Infusion
- (2008) Antoine Adenis et al. JOURNAL OF CLINICAL ONCOLOGY
- In Reply:
- (2008) David J. Brenner et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II Study of Sunitinib Malate, an Oral Multitargeted Tyrosine Kinase Inhibitor, in Patients With Metastatic Breast Cancer Previously Treated With an Anthracycline and a Taxane
- (2008) Harold J. Burstein et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II Trial of Sorafenib in Patients With Metastatic Breast Cancer Previously Exposed to Anthracyclines or Taxanes: North Central Cancer Treatment Group and Mayo Clinic Trial N0336
- (2008) Alvaro Moreno-Aspitia et al. JOURNAL OF CLINICAL ONCOLOGY
- Discovery of Brivanib Alaninate ((S)-((R)-1-(4-(4-Fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy)propan-2-yl)2-aminopropanoate), A Novel Prodrug of Dual Vascular Endothelial Growth Factor Receptor-2 and Fibroblast Growth Factor Receptor-1 Kinase Inhibitor (BMS-540215)
- (2008) Zhen-wei Cai et al. JOURNAL OF MEDICINAL CHEMISTRY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started